All lobbying filings

FORBES-TATE

Lobbying for NOVARTIS, INC. · Multinational biopharmaceutical company

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 18, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 1672
Maintaining Investments in New Innovation Act
HR 3037
Access to Breast Cancer Diagnosis Act of 2025
S 1500
Access to Breast Cancer Diagnosis Act of 2025
S 832
EPIC Act of 2025

Lobbying activity 6

Taxation/Internal Revenue Code

Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Health Issues

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.

Medicare/Medicaid

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.

Trade (domestic/foreign)

Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.

Budget/Appropriations

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.